Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Heatwave
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / COVAXIN 77.8% effective against coronavirus in Lancet study
India

COVAXIN 77.8% effective against coronavirus in Lancet study

COVAXIN 77.8% effective against coronavirus in Lancet study
Written by Sagar
Nov 12, 2021, 10:31 am 3 min read
COVAXIN 77.8% effective against coronavirus in Lancet study
COVAXIN's safety and efficacy data has been peer-reviewed and published.

COVAXIN's safety and efficacy data has been peer-reviewed and published in The Lancet medical journal, confirming the vaccine is 77.8% effective against COVID-19. This comes four months after the company revealed similar findings in a published pre-print study. COVAXIN is India's first indigenous vaccine against the coronavirus and is one of the six vaccines that have been approved in the country.

Context
Why does it matter?
  • The study reaffirms COVAXIN's position as a safe and effective jab against COVID-19.
  • It helps brush off hesitancy and doubts triggered by frequent delays in its data analysis and approvals by top health regulators around the world.
  • Just last week, the vaccine had secured the crucial Emergency Use Listing (EUL) from the World Health Organization (WHO).
Details
Efficacy analysis done on 130 cases

The efficacy analysis was done after the evaluation of 130 confirmed COVID-19 cases with 24 observed in the vaccine group and 106 in the placebo group. The vaccine's developer Bharat Biotech had carried out Phase-3 trial on over 25,000 volunteers across 25 sites in India. It had found the shot to be 93.4% effective against severe symptomatic cases and 63.6% effective against asymptomatic disease.

Vaccine
COVAXIN is an inactivated virus-based shot

COVAXIN is an inactivated virus-based vaccine. It is India's second-most prevalent coronavirus vaccine and was cleared here in January this year. It has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research's (ICMR) National Institute of Virology (NIV). As of November 3, over 12 crore doses of COVAXIN have been administered to the eligible population across India.

Statement
'Validates our commitment to data transparency'

"The peer review of COVAXIN's Phase-3 clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer review standards of world-leading medical journals," Krishna Ella, chairman of Bharat Biotech, said in a statement. "This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech," Ella added.

WHO nod
COVAXIN got WHO nod after a long wait

COVAXIN had received WHO's approval for Emergency Use Listing earlier this month. The EUL came months after Bharat Biotech submitted a request as it was repeatedly delayed over insufficient trial data. The nod has paved the way for more and more countries to recognize the jab for international travel. The company says its emergency-use authorization application is being processed in at least 50 countries.

Quote
Negativity hurt us, says Ella

Ella said that negativity from a section of the media and politicians affected COVAXIN's WHO approval process. "The way anti-things happen, that has hurt us more. I want people to realize instead of criticizing just ask us, we will tell the truth," he said.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Sagar
Sagar
Twitter
Sagar covers national news for NewsBytes. He has previously worked as an editorial intern at NDTV. Over the course of his near three-year career, Sagar has gained experience in news writing, copy editing, and video production. He holds a Bachelor's degree in Journalism and Mass Communication from the University of Delhi.
Latest
Related
Latest
5 surprising uses of toothpaste
5 surprising uses of toothpaste Lifestyle
2022 Benda BD300 cruiser goes official with sporty looks
2022 Benda BD300 cruiser goes official with sporty looks Auto
Kymco Krider 400 arrives in global markets with sporty design
Kymco Krider 400 arrives in global markets with sporty design Auto
Your guide to traveling to Spiti Valley
Your guide to traveling to Spiti Valley Lifestyle
Fourth-generation Hyundai TUCSON breaks cover in India; launch in late-2022
Fourth-generation Hyundai TUCSON breaks cover in India; launch in late-2022 Auto
Related
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension India
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
COVAXIN, Covishield will now be available in hospitals and clinics
COVAXIN, Covishield will now be available in hospitals and clinics India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022